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Ingestion ofarsenic, both from water supplies and medicinal preparations, is known tocause skin cancer. The evidence
assessed here indicates that arsenic can also cause liver, lung, kidney, and bladder cancer and that the population cancer
risks due to arsenic in U.S. water supplies may be comparable to those from environmental tobacco smoke and radon in
homes. Large population studies in an area ofTaiwan with high arsenic levels in well water (170-800 jAg/L) were used to
establish dose-response relationships between cancer risks and the concentration of inorganic arsenic naturally present
in water supplies. It was estimated that at the current EPA standard of50 ug/L, the lifetime risk ofdying from cancer of
the liver, lung, kidney, or bladder from drinking 1 L/day of water could be as high as 13 per 1000 persons. It has been
estimated that more than 350,000 people in the United Statesmay be supplied with water containing more than 50 yg/L
arsenic, and more than 2.5 million people may be supplied with water with levels above 25 Ag/L. For average arsenic levels
and waterconsumption patterns in the United States, the risk estimate was around 1/1000. Although further researh is
needed to validate these findings, measures to reduce arsenic levels in water supplies should be considered.
Introduction
Arsenic is a ubiquitous element present in various compounds
throughout the earth's crust. It was identified in ancient times;
the Greek alchemist Olympiodorus reportedly obtained metallic
arsenic by roasting one of its sulfides. The use ofarsenical com-
pounds increased greatly during the 18th and 19th centuries, in-
cluding use in pigments and dyes, in preservatives of animal
hides, in glass manufacture, agriculturl pesticides, and various
pharmaceutical substances.
The first described health effect, reported by Agricola in De
Re Metallica in 1556 (1), involved arsenical cobalt, which ate
away the skin of the hands ofworkmen. In 1888 Hutchison first
described carcinoma ofthe skin in patients treated with arsenical
mixtures for psoriasis and other skin conditions (2). Subsequent
investigations have confirmed that ingestion of inorganic arsenic
can cause skin cancer and that inhalation of inorganic arsenic can
cause lung cancer (3).
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Both organic and inorganic arsenic are present in varying
amounts in food. Fish, for example, contain relatively high con-
centrations of organic arsenic. However, inorganic forms of
arsenic are much more toxic than the organic forms. Inorganic
arsenic can be present as either arsenate [As(V)J or arsenite
[As(EI)]. Although As(III) is more toxic, human metabolism of
As(V) involves reduction to As(III) before undergoing detoxifica-
tion by methylation (4).
Arsenic is present in soil at levels ranging from 0.2 to 40 Ag/g
(rarely more than 10 jAg/g) and in urban air at levels around 0.02
.sg/m3 (3), but for the general population the main exposure to
inorganic arsenic is through ingestion. Although most major
U.S. drinking water supplies contain levels lower than 5 lAg/L, it
has been estimated that about 350,000 people might drink water
containing more than 50 lsg/L (5), the standard for arsenic set by
the U.S. Environmental Protection Agency (EPA).
Cancer risk estimates attributed to ingested arsenic have been
based on skin cancer risks alone. There is now sufficient evi-
dence to consider other internal and more fatal cancers caused
by ingested arsenic as well. The purpose of this paper is to pre-
sent the findings of a cancer risk assessment of ingestion of in-
organic arsenic in drinking water based on mortality from inter-
nal cancers.
Cancer risk assessments such as this one can be divided into
four steps: hazard identification, dose-response analysis, ex-
posure assessment, and risk characterization (6). The first sec-
tion of this paper deals with hazard identification and presents
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evidence indicating that, in addition to the well-known associa-
tion with skin cancer, ingestion of arsenic may also cause liver,
lung, bladder, and kidney cancer. A dose-response analysis and
risk extrapolation based on epidemiological studies of popula-
tions exposed to elevated levels of inorganic arsenic in their
drinking water follow, along with an assessment of the possibility
ofa threshold (i.e., a level ofexposure below which there would
be no increase inpopulation cancer risks). Exposuredataare then
described concerning the levels ofarsenic in U.S. water supplies.
Finally, results of risk characterization are presented, and the
estimates of cancer risks from ingestion ofarsenic in U.S. drink-
ing water are compared with those from two other high-risk en-
vironmental exposures: environmental tobacco smoke and radon.
Hazard Identification
The main sources of evidence for the carcinogenicity of in-
gested inorganic arsenic come from human studies, with some
limited evidence from animal studies. Results of human in-
vestigations are described first, followed by those of animal
experiments.
Human Studies
Inhalation of inorganic arsenic has been shown to cause lung
cancer in studies of smelter workers (3). However, evidence con-
sidered below suggests that systemic absorption by these workers
was insufficient to identify significantly increased risks of
cancers at other sites. Much higher systemic exposures have oc-
curred among populations ingesting water with high arsenic con-
centrations, and studies of such populations have shown in-
creased risks of skin, liver, lung, bladder, and kidney cancers.
The plausibility of a causal association is supported by ex-
posure studies that found arsenic concentrations in skin, liver,
lung, and kidney tissues (7). Animal studies generally show
arsenic to accumulate at these sites (8-12). Studies of arsenic in
humans exposed to background levels have found varying con-
centrations in different organs, including skin, lung, liver, and
kidney (13,14). This section presents a briefoverview ofthe skin
cancer evidence, and a more detailed analysis of the less pub-
licized evidence linking ingestion of inorganic arsenic with
cancer at the other more fatal sites.
Skin Cancer. Substantial evidence led the International Agen-
cy for Research on Cancer (IARC) to conclude that ingestion of
inorganic arsenic can cause skin cancer (3). Populations in coun-
tries such as Taiwan, Mexico, India, and Chile who consumed
drinking water with high levels of arsenic had high rates of skin
cancer (15-18). In Taiwan, the prevalence of skin cancer among
highly exposed males aged 60 years and older reached 25% (15).
There are also many corroborating reports of skin cancer cases
resulting from the use of orally administered arsenical medica-
tions, particularly Fowler's solution, which was widely used for
the treatment of a variety of conditions such as asthma and
psoriasis (19-22).
Liver Cancer. Angiosarcoma of the liver is a very rare tumor,
often associated with exposure to vinyl chloride or thorotrast. It
is estimated that only about 25 cases occur in the United States
each year (23). In light of its rarity, even a small number of
angiosarcoma cases associated with exposure to arsenic must be
considered meaningful.
In 1957, Roth reported three cases of liver angiosarcoma in a
series of27 autopsies performed between 1950 and 1956 among
arsenic-poisoned German vintners (24). A study in Chile found
that among a group of 16 male cancer patients exposed to high
arsenic levels through the water supply (200-2000 Ag/L), 15 had
skin carcinomas and one had a liver angiosarcoma in addition to
chronic arsenical dermatosis (25).
Falk et al. identified 168 cases of liver angiosarcoma in the
United States between 1964 and 1974 (26), ofwhom 7 had used
Fowler's solution for 6-17 years. Other individual case reports
of liver angiosarcoma associated with medicinal ingestion of
arsenic have also been published (23,27,28).
Increased mortality from primary liver cancer has also been
associated with arsenic ingestion in several studies. Luchtrath
compared the autopsy findings of 163 German winegrowers
diagnosed as having chronic arsenic poisoning with those of a
control group of 163 men of similar age (29). The winegrowers
had been heavily exposed to arsenic through drinking Haustrunk,
a wine substitute made from an aqueous infusion ofgrapes that
had a high arsenic content. Liver cancers were found in five of
the winegrowers but in none ofthe control group. These findings
are consistent with an arsenic effect but are difficult to interpret
due to possible confounding with alcohol intake.
Several epidemiological studies based on data from an area of
southwestern Taiwan known to have high levels of inorganic
arsenic in the artesian well water supply have found elevated rates
of liver cancer deaths. The most striking findings come from a
study in which the population was classified into three groups ac-
cording to the arsenic level in their drinking water (300, 300-600,
and > 600 Jg/L) (30,31). Using the number of wells in each
category and their arsenic concentrations, the EPA calculated the
weighted averages for each ofthe three groups to be 170, 470, and
800 yg/L (32). From the data given by Chen et al. (30), an in-
creasing mortality rate ratio for liver cancer can be calculated
with increasing arsenic concentration: 1.2, 1.5, and 2.5 for males
(p < 0.001) and 1.6, 2.1, and 3.6 for females (p < 0.001) (Table 1).
The similarities between residents ofneighboring villages with
respect to diets, sociodemographic characteristics, and lifestyle
make it unlikely that confounding could explain the association
between water arsenic concentrations and cancer rates.
These results are supported by a) a case-control study in the
same area that reported a strong relationship between years of
Table 1. Estimated mortality risk ratios for liver, lung, bladder,
and kidney cancer by arsenic levels in drinking water in
southwestern laiwan, using cancer mortality rates of the
general Taiwanese population as reference.'
Cancer Water levels, ztg/L p-Value for
site Sex Background 170 470 800 linear trend
Liver M 1.0 1.2 1.5 2.5 <0.001
F 1.0 1.6 2.1 3.6 <0.001
Lung M 1.0 1.8 3.3 4.5 <0.001
F 1.0 2.8 4.3 8.8 <0.001
Bladder M 1.0 5.1 12.1 28.7 <0.001
F 1.0 11.9 25.1 65.4 <0.001
Kidney M 1.0 4.9 11.9 19.6 <0.001
F 1.0 4.0 13.9 37.0 <0.001
'Based on data from Chen et al. (30).
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consumption of well water and liver cancer (33); b) a com-
parison of site-specific cancer mortality rates in the population
of the high arsenic area with those of the general Taiwanese
population (34); c) an investigation of cancer mortality of pa-
tients who suffered from blackfoot disease (BFD), a vascular
disorder endemic to southwestern Taiwan and associated with the
use ofarsenic-rich artesian well water (35); and d) an ecological
study ofcancer mortality rates and arsenic levels in the drinking
water of 314 townships in Taiwan (36).
In summary, a causal association between ingested arsenic and
liver cancer is supported by a series of case reports concerning
angiosarcoma of the liver, an investigation of arsenic-poisoned
winegrowers in Germany, and several studies in southwestern
Taiwan where drinking water has a naturally high arsenic
content.
Lung Cancer. Although inhaled arsenic is a well-known lung
carcinogen (3), little attention has been given to the evidence
relating lung cancer to arsenic ingestion. A number of case
reports link lung cancer to cutaneous signs of arsenicism
resulting from ingestion (28,37-39). For example, Robson and
Jelliffe described six patients with both lung tumors and skin
disease characteristic of arsenic exposure, all ofwhom had used
medications containing arsenic (39). Case reports of a common
cancer such as lung cancer are not convincing by themselves, but
the following epidemiological studies provide strong additional
evidence.
Lung cancer was found in 108 of the 163 arsenic-poisoned
winegrowers in Germany compared to only 14 among the con-
trols (29). Mortality data from the trade association listed 417
deaths of winegrowers, 242 of whom had lung carcinomas.
Although the winegrowers had heavy exposure to arsenic by in-
gestion, the possibility that the exposures responsible for the lung
cancers were at least partly from inhalation cannot be ruled out.
However, it should be noted that 30 of the winegrowers in the case
series had skin cancer, which has been clearly linked to high
levels of ingested arsenic, but has not been found in studies of
smelter workers who have high lung cancer risks from arsenic
inhalation.
Because data on smoking were not available, one could argue
that confounding by smoking might explain the results. However,
a high mortality odds ratio (40) of 14.7 can be calculated from the
study results, making it unlikely that smoking alone could ex-
plain the findings. The main weakness of Luchtrach's study (29)
relates to the lack of information on the choice of study subjects
so that selection bias cannot be ruled out.
A study in the province of Cordoba, Argentina, examined
mortality records for all deaths occurring between 1949 and 1959
in areas with high arsenic in drinking water (average 600 jsg/L)
and compared the cause-specific mortality rates to those of the
entire province (41). Mortality from all cancers combined was
found to be considerably higher than in the province as a whole
(24% of all deaths compared to 15%). Of the 556 deaths at-
tributed to cancer, 35% were found to be of the respiratory
organs. In addition, several other published reports have men-
tioned elevated rates of lung cancer among patients with arsenic-
related skin disorders in several areas of Argentina where levels
of arsenic in drinking water are known to be high (42,43).
However, these findings can only be considered suggestive
evidence because they are based on observations from der-
matological practices, with little or no information on back-
ground rates, case selection, length and completeness offollow
up, or smoking habits.
The studies in southwestern Taiwan, described above in the
section on liver cancer, also show evidence of elevated lung
cancer mortality rates. When the population in the arsenic-rich
area was divided in three groups according to the arsenic levels
in drinking water, a clear dose-response relationship was ob-
served (30). As shown in Table 1, increasing water arsenic con-
centrations (170, 470, and 800 tg/L) resulted in mortality rate
ratios for lung cancer of 1.8, 3.3, and 4.5 for males, and 2.8, 4.3
and 8.8 for females, respectively, using lung cancer mortality in
the general Taiwanese population for comparison.
The results of the case-control study carried out in the same
area showed a linear trend between lung cancer rates and years
of exposure to well water (p < 0.01), which persisted in a multi-
ple regression analysis that controlled for the effects ofsmoking
(33). Similar findings were reported in other mortality studies
in the same area (34,35) and in the recent ecological study car-
ried out in all of Taiwan (36). In summary, the results of epi-
demiological studies provide evidence that ingested inorganic
arsenic increases the risk of lung cancer.
Kidney and Bladder Cancer. The Taiwanese investigation of
cancer mortality described above also found a clear dose-
response relationship between arsenic water levels and bladder
and kidney cancer (30). In order of increasing water arsenic con-
centrations (170,470, and 800 tg/L), the corresponding mortality
rate ratios for bladder cancer were 5.1, 12.1, and 28.7 for males,
and 11.9, 25.1, and 65.4 for females, and for kidney cancer, 4.9,
11.9, and 19.6 for men and 4.0, 13.9, and 37.0 for women (see
Table 1). As with liver and lung cancer, the findings were sup-
ported by a case-control study showing a dose-response rela-
tionship between bladder cancer and years ofartesian well water
consumption (p < 0.01) after controlling for the effects of smok-
ing, tea consumption, and other dietary factors (33). Results of
other studies in the same area ofTaiwan provide additional sup-
port for the association (34-36,44).
The magnitude ofthe above mortality rate ratios forbladder and
kidney cancers is such that confounding by some other risk fac-
tor is most unlikely to be the explanation. The evidence suggests
a causal relationship. Similar associations have so far not been
reported elsewhere in relation with arsenic ingestion, but no other
populations ofcomparable size and exposure have been studied.
The mortality rate ratios for these two cancers are sufficient-
ly high to ask why increased risks have not been consistently
detected in studies of smelter workers, Based on urinary arsenic
levels of workers in a large smelter study that reported marked
increases in lung cancer due to arsenic inhalation (45), one can
estimate an average cumulative absorbed dose of arsenic of ap-
proximately 3000 mg. This is less than half the cumulative dose
achieved by a 60-year-old worker drinking 2 L of water/day at the
lowest exposure level (170 ug/L) in the studies in Taiwan. If, on
the other hand, one considers the group ofworkers with highest
cumulative exposure, the estimate of systemic absorption
becomes comparable to that of Taiwan. However, rates of these
cancers are not given. Thus the failure to detect significant in-
creases in bladder and kidney cancer among smelter workers
may be due to a combination of their lower systemic exposure to
arsenic and lack of examination of the highest exposed groups.
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Nevertheless, the findings concerning arsenic smelters are not
completely negative. A recent study ofarsenic-poisoned workers
and residents of a mining town in Japan found them to have
significantly elevated rates ofcancers ofthe bladder, kidney, and
other urinary organs (standardized mortality ratio [SMR] = 766,
95% confidence interval [C.I.] 136-2795) in addition to lung
cancer (SMR = 566, 95% C.I. 266-1119) (46). Although the
urinary tract cancer SMR of 766 was based on only two cases,
it is significant that both were accompanied by Bowen's disease
(characterized by skin lesions and associated with arsenic inges-
tion). Further study of kidney and bladder cancer mortality
among smelter workers by duration and intensity ofexposure is
warranted.
Animal Studies
Arsenic is unique in being the only established human car-
cinogen that has not been established as a carcinogen in rodents.
The IARC concluded that the results ofanimal studies supply on-
ly limited evidence of carcinogenicity (47). Although most
arsenic inhalation bioassays have produced negative results, two
groups of investigators reported positive findings in experiments
involving intratracheal administration of arsenic (48-50).
Bioassays involving oral exposure to arsenic have produced in-
conclusive results. Studies in mice given drinking water with
arsenic levels ranging from 4.0 to 100 mg/L did not show in-
creased cancer rates (51-53).
The effects ofarsenic have also been examined inmouse strains
that have a high background incidence rate of spontaneous
tumors. The results from these investigations have been incon-
sistent. In one study, sodium arsenite appeared to inhibit the
development and growth ofprecancerous cell populations, but
once tumors developed, the growth rate was faster and the in-
cidence of multiple tumors and metastases was higher in the
arsenic-treated animals (54,55). In another study, trivalent or
pentavalent arsenic given in drinking water in conjunction with
urethane decreased the number and size of tumors (56,57).
Another group ofinvestigators reported increased kidney and
liver tumors in rats treated with either trivalent or pentavalent
arsenic (58-60). In their latest study, intact male Wistar rats were
injected with either saline or 30 mg/kg of diethylnitrosamine
(DEN), a known carcinogen. After 1 week each group was sub-
divided into four treatment groups receiving 0, 160 mg/L As(Lll),
160 mg/L As(V), or 80 mg/L dimethylarsonic acid (DMA) in
drinking water. The animals were sacrificed after 10, 15, or 24
months of exposure.
Based on limited statistical analysis, the authors concluded that
As(E) and DMA were promoters for DEN-initiated hepato-
cellular carcinomas and that As(SI) and As(V) were promoters
for DEN-initiated renal tumors. Using data provided in the
report, we have conducted additional analyses using the Mantel-
Haenszel chi-square test (61). In view of the relatively small
number of animals per group (Table 2), the treatment groups
were pooled across sacrifice time points first and then across
treatments. The results of this analysis show an increase in tumor
incidence, both with and without DEN, for each form ofarsenic.
The overall effect of arsenic on liver neoplastic nodules and
kidney tumors was not likely to be attributable to chance (p =
0.012 and 0.013, respectively). It is noteworthy that the increased
alble 2. Carcinogenic effects of arsenic on intact rats.
Sacrifice time points, months
Treatment group 10 15 24 p-Value
Liver neoplastic nodules
Saline control 0/14b 0/11 0/16
Saline + As(II) 0/22 0/22 2/7 0.08c
Saline + As(V) 0/14 0/16 1/5 NA
Saline +DMA 0/10 0/21 2/6 0.06
DEN control 0/14 1/8 3/6 <0.1C
DEN + As(III) 0/13 3/14 5/6 0.22d
DEN + As(V) 0/9 4/9 4/7 0.2Id
DEN + DMA 1/14 2/11 7/8 O.IId
Kidney tumors
Saline control 1/14 0/11 1/16
Saline + As(III) 0/22 2/22 2/7 0.28c
Saline + As(V) 2/14 0/16 2/5 0.12c
Saline + DMA 0/10 0/221 1/6 0.28c
DEN control 0/14 0/8 2/6 0.42c
DEN + As(lII) 3/13 4/14 2/6 0.05d
DEN + As(V) 3/10 4/9 4/7 < 0.01d
DEN + DMA 1/14 0/11 3/8 0.45d
Abbreviations: DMA, dimethylarsonic acid; DEN, diethylnitrosamine; NA,
not available (insufficient cell size to perform test).
'Based on data from Sirachi et al. (60).
bNumber of animals affected/number of animals in treatment group.
CPboled across sacrifice time points and compared to saline controls using
Mantel-Haenszel chi-square test (p-values are for one-tailed testing).
dPooled across sacrifice time points and compared to DEN controls using
Mantel-Haenszel chi-square test (p-values are for one-tailed testing).
tumor incidence observed in rats occurred in liver and kidney,
two of the target organs observed in humans. However, the fact
that treated rats had significantly lower weights than control rats
weakens the evidence from this study because it raises the
possibility that increased cancer rates were an indirect effect of
exposure affecting nutritional status.
The above data analysis provides some evidence that high
doses of ingested arsenic may result in carcinogenic activity in
rats. Although this effect was not seen in mice, the levels of
arsenic in their drinking water were lower, and micemay be pro-
tected by methylating arsenic more rapidly than rats (62).
Dose-Response Analysis
Skin Cancer
Skin cancer risk estimates have been derived based on the
study by Tseng et al., which involved a large population in the
endemic area ofTaiwan (15). Using skin cancer prevalence rates
from populations having different arsenic levels in their drink-
ing water, a clear dose-response relationship was observed.
Brown et al. (63) calculated the lifetime risks of skin cancer to
be 1.3/1000 for males and 0.6/1000 for females per microgram of
arsenic per day. In the section that follows, we examine the dose-
response relationships between arsenic levels in water and
cancers ofthe lung, liver, bladder, and kidney and extrapolate the
risk to the current U.S. drinking water standard of50 jzg/L. We
focus on these sites because mortality from these cancers is much
higher than from skin cancer.
Other Cancers
Estimates ofthe risks ofbladder, kidney, lung, and liver cancer
were based on data from southwestern Taiwan, where a dose-
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response gradient between arsenic water levels and cancer mor-
tality rates for these sites was observed (30). The statistical
testing consisted of a trend analysis ofproportions using linear
regression (64). The well water concentrations were divided into
three categories, with weighted average concentrations estimated
to be 170, 470, and 800 lAg/L (32). The mortality cancer rates
reported by Chen et al. for the three arsenic levels were used
(30), weighted by the person-years of exposure at each dose
group, as given by Wu et al. (31), assuming that all cancer deaths
for the four sites occurred in persons more than 20 years ofage.
The background population mortality rates for Taiwan were used
as intercepts. The results ofthe regression analysis are shown in
Table 3 and plotted in Figure 1, where it can be seen that the
findings are reasonably consistent with linear dose-response
relationships.
Tbble 3 Regreson analysisofarsenic in drinlin waterand cancerm lity
rates in Taiwan.
Cancer Background Slope Standard error p-Value for
site Sex mortality' estimateb of the slope linear trend
Liver M 28.0 0.041 0.008 <0.001
F 8.9 0.026 0.005 <0.001
Lung M 19.4 0.091 0.007 <0.001
F 9.5 0.083 0.004 <0.001
Bladder M 3.1 0.083 0.003 <0.001
F 1.4 0.091 0.002 <0.001
Kidney M 1.1 0.026 0.002 <0.001
F 0.9 0.033 0.002 <0.001
aAge-adjusted mortality per 100,000.
bThe slope represents the increase in cancer mortality rate (per 100,000) per
microgram increase of arsenic in drinking water, based on data from Chen et al.
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FIGURE 1. Age-adjusted mortality rates for liver, lung, bladder, and kidney
cancer by the arsenic concentrations in drinking water and plots of linear
regressions for data from studies in Taiwan (30,31).
Is There a Threshold?
Inorganic arsenic is methylated into less toxic, organic forms
at various sites in the body, in particular the liver and kidney.
Urinary excretion of inorganic arsenic is thus a combination of
unchanged inorganic arsenic and its methylated forms, DMA and
MMA (dimethylarsonic and monomethylarsinic acids). It has
been suggested that one might expect a threshold for the car-
cinogenic effect ofarsenic ingestion ifmethylation activity had
to be saturated before cancer risks increased (32,65). Ifthe car-
cinogenic effects of arsenic are caused only by the inorganic
forms, and if ingested inorganic arsenic only reaches target
organs when methylation is saturated, then one might expect a
threshold for arsenic ingestion below which there would be no
risk of it causing cancer. If, on the other hand, some inorganic
arsenic always passes through the liver unchanged and reaches
target organs, but the proportion remaining in inorganic form in-
creased with increasing ingestion ofarsenic, then one would ex-
pect a sublinear dose-response relationship between ingested
arsenic and cancer risk.
A study in mice showed that increasing the dose of either
As(mI) or As(V) two orders of magnitude resulted in a 2- to
2.5-fold increase in the proportion excreted in the inorganic form
(62). The data on methylation in humans, however, does not
show evidence for such a relationship. Table 4 illustrates the
distribution ofurinary metabolites ofinorganic arsenic excreted
after different levels of exposure. Studies of individuals with
background exposure found that unmethylated inorganic arsenic
constituted between 15 and 32% ofthe urinary excretion of the
metabolites of inorganic arsenic (66-70). Occupationally ex-
posed populations had values within the same range (67,69,70),
as well as human volunteers who ingested measured doses of in-
organic arsenic (66,68,71). It can be clearly seen in Table 4 that
even at low background levels of arsenic exposure methylation
is far from complete.
Table 4. Relative distribution of urinary metabolites of inorganic arsenic
(unchanged In-As, MMA, DMA) after exposure to different levels of
inorganic arsenic.
Number % Excreted in urine
Source of exposure exposed In-As MMA DMA Reference
Background 148 32 32 36 (67)
4 18 4 78 (66)
16 18 4 78 (68)
6 18 16 65 (69)
41 15 20 66 (70)
102 23 7 70 (80)
Ocupational
Smelter workers 9 19 20 61 (69)
Smelter workers 30 20 22 66 (70)
Glass workers 38 23 15 62 (67)
Gallium arsenide 27 32 9 61 (80)
workers
Experimental, Ag/kg/Lb
0.000143 6 27 21 51 (71)
7.1 3 25 21 54 (68)
9c 1 16 34 50 (66)
18c 1 7 20 73 (66)
35.5c 1 19 21 60 (66)
71.5c 1 26 32 42 (66)
Abbreviations: In-As, inorganic arsenic; MMA, monomethylarsinic acid;
DMA, dimethylarsonic acid.
'When a number exposed is > 1, numbers represent group mean values.
bExperimental doses are via ingestion of arsenic in water, assuming a body
weight of 70 kg for human studies.
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A recent paper (72) seems to contradict this evidence by show-
ing that at low exposures methylation is near complete. However,
it should be noted that this inference cannot be made based on the
way the data were analyzed: nondetectable values were averaged
in as zero. If, in fact, each inorganic arsenic species was just at
the detection level of 0.5 ytg/L, then the total inorganic arsenic
would be roughly around 20%. Therefore, the evidence de-
scribed above does not support a threshold for inorganic arsenic
carcinogenicity.
Exposure Assessment
Current dietary intake oftotal arsenic in U.S. adults, excluding
tap water, has been estimated to be around 45-50 pg/day (32,73).
Most of the arsenic derives from seafood, meat, and poultry
(80%) and grains and cereals (17 %). Although seaood has a high
arsenic content, only about 5-10% is in the inorganic form (74),
and the organic forms (mainly arsenobetaine) are excreted un-
changed (69). The EPA estimated the average total intake of in-
organic arsenic from food, water and other beverages to be about
17 pg/day, of which 5 pg/day come from drinking water (32).
Thus, for the majority ofthe U.S. population, about 30% of in-
gested inorganic arsenic comes from drinking water. However,
if inorganic arsenic is present at the current water standard (50
sg/L), drinking water could contribute almost 100 pg more to the
daily intake of inorganic arsenic. This would represent about
90% of the daily intake. Even at half that concentration, water
would still be by far the main source of inorganic arsenic (more
than 80%).
Based on several national water surveys, the EPA estimated the
national occurrence of inorganic arsenic in drinking water (5).
Although most public water supplies contain levels below 5
pug/L, it is estimated that about 350,000people might drink water
containing more than 50 pg/L, and about 2,500,000 people drink
water containing more than 25 Ag/L.
Risk Characterization
Risk Estimation for the U.S. Population
The estimated mortality rate ratios for males and females are
presented in Table 5. Risks for each cancer were extrapolated
linearly to an arsenic concentration of50 ,g/L from the regres-
sion lines shown in Figure 1. Based on the EPXs assumption of
daily water consumption rates of 3.5 L for men and 2.0 L for
women in the hot climate of Taiwan (32), mortality rate ratios
(RR) were calculated for a daily water intake of 1 L/day. The ex-
cess rate ratios, RR-1, were multiplied by the U.S. background
rate (B), which was estimated by dividing the number ofdeaths
from each cancer by the total number of deaths, using figures
from U.S. Vital Statistics for the year 1985 (75). Lifetime risks
ofdeath from cancers ofthe liver, lung, bladder, and kidney were
thus derived for consumption of 1 L/day in the United States
(Table 5). The estimates ofdying from one ofthese cancers due
to a lifetime consumption ofwater containing 50 pg ofarsenic/L
at a rate of 1 L/day were 9.4/1000 for males and 17.3/1000 for
females, averaging around 13/1000. It is important to emphasize
that, contrary to most risk assessments of the type presented
here, the calculation of risks involve only a small extrapolation
from clearly demonstrated effects at 170 ug/L and above.
Table 5 Estimation of lifetime risks per 1000 of dying from cancer of the
kidney, bladder, lung, and liver from consumption of 1 L/day ofwater with
an arsenic concentration of 50 jAg/L.
Estimated
Cancer mortality rate Rate ratio
site/sex ratio (RR)b Bc B(RR-I)d
Liver
Male 1.07 1.02 3.67 0.1
Female 1.14 1.07 2.82 0.2
Lung
Male 1.24 1.07 76.4 5.3
Female 4.25 2.63 39.2 8.6
Bladder
Male 2.34 1.38 6.08 2.3
Female 4.25 2.63 3.14 5.1
Kidney
Male 2.18 1.34 5.02 1.7
Female 2.83 1.92 3.64 3.4
Total risk per daily consumption of 1 L of water
Male 9.4
Female 17.3
Average of male and female risks
13.4
aBased on data from southwestern Taiwan (30,31).
bRR = estimated mortality rate ratio calculated for water consumption of 1
L/day.
CB = U.S. background risk per 1000.dB(RR.- 1) = lifetime risk per 1000 from water consumption of 1 L/day.
The male/female difference in risk estimation is due in part to
the lower background cancer rates for women in Taiwan, thus
making the rate ratios higher for those exposed. The EPA
assumption that men in Taiwan drink almost twice as much
water as women also decreases the estimated carcinogenic
potency ofarsenic for men compared to women. Nevertheless,
the male/female risk estimate differences are within the range
of uncertainty of a risk assessment such as the one presented
here, and there is no biological reason to consider females to be
at higher risk. For these reasons the male and female risks were
averaged for application to the general population.
Although there are no accurate data on the average arsenic
levels in drinking water for the United States, estimates range
from 2.0 to 2.5 Ag/L (7,32). Using the estimated average water
intake in the United States of 1.6 L/day (76) and an average
arsenic water level of 2.5 pg/L, linear extrapolation yielded an
estimated lifetime risk of dying from liver, lung, bladder or
kidney cancer due to arsenic in drinking water of 1/1000.
Some animal studies seem to indicate that a protein-deficient
diet increases arsenic toxicity by decreasing methylation capaci-
ty (8). It has been hypothesized that populations consuming in-
adequate diets and exposed to high arsenic levels may thus be
more susceptible to arsenic toxicity (32). If nutritionally inade-
quate diets among the Taiwanese population exposed to arsenic
made them more susceptible to the carcinogenic effects of
arsenic, the extrapolated risk estimates for the average U.S.
population would be too high. However, the validity of the
Taiwanese findings would remain unchanged, as the populations
in Taiwan drinking water with different levels ofarsenic were
all similar with respect to lifestyle, education, and occupation
(33). Variation in the detoxification of arsenic by methylation,
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either due to nutritional or genetic factors, has not yet been in-
vestigated in humans and is an important area of research that
needs to be addressed.
Comparison with Cancer Risks from Other
Environmental Exposures
The estimates ofcancer risks associated with the current U.S.
drinking water standard derived above place arsenic at the
forefront of cancer risks associated with environmental ex-
posures. There are only two known environmental exposures
with comparable risks, namely, environmental tobacco smoke
(ETS) and radon in homes. In the case ofETS, exposure occurs
from several sources, mainly from living with a smoker or work-
ing with smokers. The National Research Council estimates the
lifetime risk of lung cancer attributable to ETS to range from 4
to 10/1000 (77).
Considerable attention has been given in recent years to the in-
creased risk of lung cancer caused by indoor radon exposure
(78). Nero et al. (79) estimated that the average indoor concen-
tration of radon in U.S. homes poses a lifetime lung cancer risk
of about 3/1000. Table 6 compares the cancer risks from ETS,
radon, and arsenic in drinking water.
EvidenceThatArsenicisaBeneficialMicronutrient
Policy decisions arising from potential cancer risks due to in-
organic arsenic in drinking water need to consider the possibility
that arsenic is a beneficial micronutrient. Signs ofarsenic dep-
rivation, including depressed growth and abnormal reproductive
function, have been described for the chicken, goat, pig, and rat
(32), indicating the possibility that arsenic, at least in inorganic
form, is an essential nutrient. Based on these experimental data,
various estimates ofhuman nutritional requirements have been
made, ranging from 10 to 30 itg/day (32). However, the relevance
ofthe experimental animal data to humans is unclear. No human
arsenic deficiency syndrome has yet been reported, even though
many water supplies contain less than 2.5 Ag/L. In contrast to
humans, rats sequester arsenic in red blood cells (11), and it is
possible that the other animal species in the deprivation studies
also differ from humans in arsenic storage and metabolism.
Human requirements for inorganic arsenic warrant more in-
vestigation, but there is no evidence to suggest that deficiency ef-
fects would result from reducing levels of arsenic in water sup-
plies containing above-average concentrations.
Table 6. Esim lifetime risks ofdying from cancer due to exposure to dif-
ferent environmental carcinogens in the United States.
Carcinogen Risk
Environmental tobacco smoke (passive smoking)
Low exposure (not married to a smoker) 4/1000
High exposure (married to a smoker) 10/1000
Radon in homes
Average exposure 3/1000
High exposure (1-3% of homes) 20/1000
Arsenic in drinking water (1.6 L/day)
2.5 jtg/L (U.S. estimated average) 1/1000
50 Ig/L (U.S. water standard) 21/1000
Conclusions
On the basis of the overall consistency of results from epi-
demiological studies, there is persuasive evidence that inorganic
arsenic is a cause of human cancer at several sites. A causal
association between ingested arsenic and skin cancer has
previously been established. The evidence presented here
strongly supports a causal relationship between ingested arsenic
and both liver and lung cancer. There is also evidence from
Taiwan that arsenic causes human kidney and bladder cancer,
although further studies are needed to confirm these findings.
Additional research also needs to be conducted concerning
arsenic methylation and its relationship to genetic, dietary, or
other lifestyle factors, which may affect individual differences
in susceptibility to the carcinogenic effects of arsenic.
Although the drinking water of the majority of the U.S.
population has levels of arsenic considerably below the stan-
dard, it is estimated that about 350,000 people drink water with
levels above the standard, and more than 2.5 million people are
supplied with water containing more than 25 1sg/L. The com-
parisons with ETS and radon, two recognized carcinogens of
public health concern, serve to point out the serious environmen-
tal cancer risks posed by arsenic in drinking water. Although
further research is needed to validate the findings of this risk
assessment, measures should be taken to reduce arsenic levels
in water supplies.
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